H. Zetterberg

Plasma eMTBR-tau as a robust biomarker for Alzheimer's disease tangle pathology up to 10 years before death

Scalable and accessible biomarkers of neurofibrillary tangle pathology are needed for Alzheimer's disease prognosis, diagnosis and monitoring. Here, we show that a blood-based immunoassay for an endogenously-cleaved eMTBR-tau fragment of tau protein is strongly associated with autopsy-diagnosed Alzheimer neuropathologi...

Plasma immune signatures associate with neurodegeneration in frontotemporal lobar degeneration

Plasma multiplex proteomics identified complementary dimensions of neuroaxonal injury and immune dysregulation across frontotemporal lobar degeneration-related syndromes and candidates for independent biomarker validation and mechanistic investigation are identified.

Blood Biomarkers of Alzheimer's Disease Neuropathology, Cognition, and Response to a Multidomain Lifestyle Intervention: Secondary analysis of the FINGER Randomized Controlled Dementia Risk Reduction Trial

Data-driven mapping of known and novel fluid biomarker progression profiles in genetic frontotemporal lobar degeneration

The model’s accurate estimation of disease stages underscores the value of DEBM for patient stratification, offer a promising tool to support clinical trial design and provide a temporal ordering of multiple CSF proteins.

Presymptomatic plasma biomarkers in autosomal dominant Alzheimer's disease: sequence and timing.

Multiple plasma proteins are elevated in presymptomatic and symptomatic ADAD mutation carriers relative to non-carriers, and combining biomarkers may help in staging presymptomatic AD and optimise clinical trial inclusion.

Clinical and Biologic Characterization of a 3-Level Centiloid-Based Classification of Amyloid PET.

Findings support a 3-level interpretation of amyloid PET beyond binary classification and highlight the clinical relevance of the intermediate zone, which delineates biologically and clinically distinct stages along the amyloid continuum.

Metabolism Pathway Blood Proteomic Differences in Lewy Body Dementia Compared to Alzheimer’s Disease

Dementia with Lewy Bodies (DLB) is the most common neurodegenerative dementia after Alzheimer’s disease (AD), but it remains challenging to diagnose due to overlapping symptoms and mixed pathologies. This pilot study tested whether DLB has different metabolic blood proteomic profiles compared to AD and controls. Serum...

Plasma Biomarkers for Neocortical Tau Burden.

This multicohort study demonstrated how including additional plasma proteins significantly enhanced the performance of p-tau217 in predicting advanced tau pathology among amyloid-positive individuals, suggesting a multiprotein approach may offer a viable and scalable alternative to tau PET staging in clinical or resear...

Exploring longitudinal relationships among Alzheimer's disease biomarkers

While most studies of Alzheimer's disease (AD) examine cross‐sectional relationships among biomarkers, longitudinal relationships are also highly relevant.

Predicting continuous amyloid PET levels with CSF and plasma brain‐derived p‐tau217

Conventional phosphorylated tau (p‐tau)217 reliably identifies amyloid positron emission tomography (PET) positivity, but its ability to capture the full Aβ continuum is limited.

CSF fibrinogen predicts longitudinal Tau accumulation in cognitively unimpaired older adults

Fibrinogen represents a sensitive marker of BBB leakage, but whether it modifies longitudinal tau progression in cognitively unimpaired (CU) individuals remains unknown.

Lifestyle and psychosocial protective factors drive healthy aging and modulate inflammatory and metabolic pathways.

The present study paves the way for further investigations on the biological mechanisms underlying resilient aging, while further demonstrating the key protective role of individual habits and psychosocial characteristics during the life course.